Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vertex Pharmaceuticals (NQ: VRTX ) 495.26 +3.00 (+0.61%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Vertex Pharmaceuticals < Previous 1 2 ... 7 8 9 10 11 12 13 14 15 ... 50 51 Next > 2 Red Flags for Bluebird Bio Stock January 10, 2024 The biotech's struggles may continue. Via The Motley Fool These 3 Stocks Have Beaten the S&P Average Return for Years and Are Likely to Continue That Trend January 10, 2024 These winners seem likely to keep up their winning ways. Via The Motley Fool Topics Stocks Exposures US Equities A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 16 Analysts January 09, 2024 Via Benzinga Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia January 09, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings January 09, 2024 Via Benzinga $1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today January 08, 2024 Via Benzinga Is Vertex Pharmaceuticals Stock a Buy Now? January 06, 2024 The biotech's prospects keep improving. Via The Motley Fool Decoding Vertex Pharmaceuticals's Options Activity: What's the Big Picture? December 27, 2023 Via Benzinga 2 low-priced gene therapy stocks to speculate on January 08, 2024 Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe Via MarketBeat Exposures Product Safety 5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday January 08, 2024 The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. Via Benzinga The Ultimate Growth Stock to Buy With $1,000 Right Now January 08, 2024 The stock, trading for about $60, has plenty of room to run. Via The Motley Fool Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings January 07, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire 5 Top Stocks to Buy in January January 07, 2024 Start the year off right by investing in these quality businesses. Via The Motley Fool Investing Trends to Follow in 2024 January 06, 2024 We've also got Motley Fool co-founder Tom Gardner sharing an investing lesson from last year and a stock for this one. Via The Motley Fool Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 January 05, 2024 Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. Via Investor's Business Daily 2 Biotech Stocks With Huge Catalysts in 2024 January 05, 2024 Important clinical-trial readouts on the way could send these stocks soaring in early 2024. Via The Motley Fool Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors January 04, 2024 Gen Z stocks include companies the generation prefers to invest in while capturing the emerging economic force they represent. Via InvestorPlace Will the Biotech sector sustain its momentum in 2024? January 04, 2024 The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%. Via MarketBeat Topics ETFs The Best Stocks to Invest $1,000 in Right Now January 04, 2024 It's not too late to get in on these market beaters. Via The Motley Fool Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics January 04, 2024 CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead. Via The Motley Fool 3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition January 03, 2024 Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside. Via InvestorPlace Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Climbs to New 52-Week High January 03, 2024 Via Investor Brand Network January Has Been 1 of the Worst Months for the S&P 500 Over the Last 20 Years. Here Are 3 Stocks to Buy Anyway. January 03, 2024 These stocks are smart picks to buy now, regardless of whether the S&P 500 stocks start off 2024 poorly. Via The Motley Fool Topics Stocks Exposures US Equities 3 Biotech Stocks Set for Breakthroughs in 2024 January 02, 2024 With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. Via InvestorPlace 2 gene-editing stocks reshaping hereditary disease treatments January 02, 2024 Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Via MarketBeat Prediction: These 3 Stocks Will Soar in 2024 January 01, 2024 Investors could enjoy an especially happy new year with these great stocks. Via The Motley Fool 1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024 December 31, 2023 Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name. Via The Motley Fool Want $1 Million in Retirement? Invest $300,000 in These 3 Stocks and Wait a Decade. December 30, 2023 These stocks offer attractive risk-reward profiles. Via The Motley Fool 2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now December 29, 2023 It's been a crazy year across sectors, but winners remain. Via The Motley Fool CRISPR Therapeutics sets sights on gene-editing cures for disease December 27, 2023 On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for Via MarketBeat Exposures Product Safety < Previous 1 2 ... 7 8 9 10 11 12 13 14 15 ... 50 51 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.